Key result
Heparin with transradial access showed a trend toward reduced inpatient major cardiovascular events compared to bivalirudin with transfemoral access in patients undergoing primary PCI for STEMI.
Why the study?
The best combination of access site and anticoagulant used during primary PCI in patients presenting with ST segment elevation myocardial infarction was not known.
Does heparin with transradial access reduce MACE and bleeding complications compared to bivalirudin with transfemoral access in patients undergoing primary PCI for STEMI?
Cohort (n=1,074)
Yes
Does heparin with transradial access reduce MACE and bleeding complications compared to bivalirudin with transfemoral access in patients undergoing primary PCI for STEMI?
In patients undergoing primary PCI for STEMI, the use of heparin with radial access showed a trend toward reduced inpatient MACE compared with bivalirudin with femoral access, with no significant differences in mortality or bleeding when cardiogenic shock patients were excluded.
Answers are grounded in this paper and cite their sources.
Nonsignificant trend favoring heparin-radial access is hypothesis-generating; leaves open optimal strategy pending randomized trials in STEMI PCI.
INTRODUCTION: The best combination of access site and anticoagulant used during primary percutaneous coronary intervention (PCI) in patients presenting with ST segment elevation myocardial infarction is not known. METHODS: We conducted a retrospective cohort study of all patients >18 years of age who underwent primary PCI in 2 large regional ST segment elevation myocardial infarction centers in Massachusetts between 2012 and 2014. The cohort was divided into 3 groups: bival/fem, hep/rad, or off-protocol, based on anticoagulation and access used. We used multiple logistic regression model to compare major cardiovascular events-major adverse cardiovascular events (MACE) and bleeding complications between the 2 on-protocol groups (bival/fem and hep/rad). RESULTS: Of the 1074 patients in this study, there were 443 (41%), 501 (47%), and 130 (12%) patients in bival/fem, hep/rad, and off-protocol groups, respectively. There were significantly higher number of cardiogenic shock patients in the bival/fem compared to the hep/rad group (6.5% vs. 3.0%, P < 0.001). There was a trend toward reduced MACE in the hep/rad group compared to bival/fem (2.8 % vs. 5.1%, P = 0.068). When cardiogenic shock patients are excluded, there is no significant difference in mortality rates (bival/fem: 2.7% vs. hep/rad: 1.0%, P = 0.07) or bleeding complications between the groups (hep/rad: 4.5% vs. bival/fem: 2.1%, P = 0.06). CONCLUSIONS: In patients undergoing primary PCI, there was a trend toward reduced inpatient MACE with the use of heparin and radial access compared with bivalirudin with femoral access. In patients without cardiogenic shock, there is no significant difference in mortality or bleeding rates between the 2 groups.
No takes yet. Share an insight, caveat, or question.
Mallidi et al. (2019) conducted a cohort in ST segment elevation myocardial infarction (n=1,074). Heparin with transradial access vs. Bivalirudin with transfemoral access was evaluated on Major adverse cardiovascular events (MACE) (p=0.068). Heparin with transradial access showed a trend toward reduced inpatient major cardiovascular events compared to bivalirudin with transfemoral access in patients undergoing primary PCI for STEMI.
Synapse has enriched 10 related papers. Consider them for comparative context: